Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival
Sharareh Siamakpour‐Reihani(Duke University), Mark W. Dewhirst(Duke Medical Center), Oana Craciunescu(Duke Medical Center), Kouros Owzar(Duke University), Holly K. Dressman(Duke University), Chen Jiang, Peter M. Scarbrough(Duke Medical Center), Kimberly Blackwell(Duke University), Janet K. Horton(University of North Carolina at Chapel Hill)
Cited by 14
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|960
Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
|JNCI Journal of the National Cancer Institute|2006|923
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
|Journal of Clinical Oncology|2008|917